A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatmentnaïve, uncontrolled Type 2 Diabetes Mellitus patients.